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1. Introduction
The prevalence of diabetes is rapidly rising all over the globe at an alarming rate. Over the past 30 yr, the status of  
diabetes has changed from being considered as a mild disorder of the elderly to one of the major causes of morbidity and 
mortality affecting the youth and middle aged people. It is important to note that the rise in prevalence is seen in all six 
inhabited continents of the globe2. Type 2 diabetes represents approximately 90% of individuals with diabetes in the United 
States, while most of the remainder has type 1 diabetes. According to statistics from the Centre for Disease Control (CDC)  
diabetes is the sixth leading cause of death due to disease in the U.S., and the third leading cause among some ethnic  
populations1.
The application of nanotechnology to medicine is called nanomedicine, it is defined as:“Research and technology 
development at the atomic, molecular and macromolecular levels in the length scale of approximately 1 – 100 nanometer  
range,  to  provide  a  fundamental  understanding  of  phenomena  and  materials  at  the  nanoscale  and  to  create  and  use 
structures, devices and systems that have novel properties and functions because of their small and/or intermediate size.” 
The size domains of components involved with nanotechnology are similar to that of biological structures. For example, a  
quantum dot is about the same size as a small protein (<10nm) and drug- carrying nanostructures are the same size as some 
viruses  (<100  nm).  Because  of  this  similarity  in  scale  and  certain  functional  properties,  nanotechnology is  a  natural  
progression of many areas of health-related research such as synthetic and hybrid nanostructures that can sense and repair  
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Abstract
Nanotechnology offers  sensing technologies that provide more accurate 
and timely medical information for diagnosing disease, and miniature devices that 
can  administer  treatment  automatically  if  required.  Some  tests  such  as  diabetes 
blood sugar levels require patients to administer the test themselves to avoid the risk 
of their blood glucose falling to dangerous levels. Certain users such as children and 
the  elderly  may  not  be  able  to  perform  the  test  properly,  timely  or  without 
considerable pain. Nanotechnology can now offers new implantable and/or wearable 
sensing  technologies  that  provide  continuous  and  extremely  accurate  medical 
information. In the long run, nanotechnology will clearly open up many routes to 
treatments and cures for diabetes, as it will for many of the diseases and conditions 
that  currently  plague  mankind.  Nanotechnology  offers  some  new  solutions  in 
treating diabetes mellitus. Boxes with nanopores that protect transplanted beta cells 
from the immune system attack, artificial pancreas and artificial beta cell instead of 
pancreas transplantation, nanospheres as biodegradable polymeric carriers for oral 
delivery of insulin are just some of them. The abilities of nanomedicine are huge,  
and nanotechnology could give medicine an entirely new outlook. Whilst some of 
these technologies are quite far-fetched, there is evidence that we will see significant 
advances in the treatment and management of diabetes quite soon. The purpose of 
this  review  is  to  throw  more  light  on  the  recent  advances  and  impact  of 
nanotechnology on biomedical sciences to cure diabetes.
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biological lesions and damages just as biological nanostructures (e.g. white-blood cells and wound-healing molecules)2
2. Diabetes Mellitus
Diabetes  (diabetes  mellitus)  is  a  metabolic  disorder  which  results  in  high  levels  of  blood glucose.  It  can  be 
classified as either Type 1 or Type 2, depending on the reason for the high glucose levels. Type 1 diabetes means that the  
pancreas cannot produce insulin (a  hormone which enables  the uptake of  glucose by the liver,  muscle and fat  tissue), 
whereas Type 2 means that the body's cells do not respond to the presence of insulin.  Whilst Type 1 diabetes can be fatal if 
untreated, most patients today survive into old age - however, they must inject insulin several times a day to allow their  
body to use the glucose from their food. Our understanding and ability to treat insulin has been improving steadily, ever 
since the first insulin injections were carried out in the early 1920s by Banting and Best. Despite all the advances which  
have been made, insulin cannot be cured altogether, and a good deal of research effort is aimed at improving quality of life  
for diabetic patients, making their glucose tests and insulin injections as easy and non invasive as possible, and potentially  
devising a permanent cure for diabetes.1, 3 
2.1 Use of nanotechnology in the detection of insulin and blood sugar: Current methods of blood glucose monitoring are 
invasive and often painful. The finger-prick test has been associated with non-adherence to treatment regimes by diabetic 
patients because of this, but it  also has very limited accuracy - it  cannot be performed during other activities,  such as  
driving, or sleeping, and its intermittent  nature means that  it  can miss important  and potentially dangerous spikes and 
fluctuations in blood glucose levels in between tests. 
Several improved methods for non-invasive, continuous monitoring of blood glucose have been proposed in the 
last few years. Many of these take advantage of the advances in medical technology made possible by nanotechnology.
A new method that uses nanotechnology to rapidly measure minute amounts of insulin and blood sugar level is a 
major step toward developing the ability to assess the health of the body’s insulin-producing cells.4 It can be achieved by 
following ways-
2.1.1 By microphysiometer: The microphysiometer is built from multiwalled carbon nanotubes, which are like several flat 
sheets  of  carbon  atoms  stacked  and  rolled  into  very  small  tubes.  The  nanotubes  are  electrically  conductive  and  the 
concentration of insulin in the chamber can be directly related to the current at the electrode and the nanotubes operate  
reliably at pH levels characteristic of living cells. Current detection methods measure insulin production at intervals by 
periodically collecting small samples and measuring their insulin levels. The new sensor detects insulin levels continuously 
by measuring the transfer of electrons produced when insulin molecules oxidize in the presence of glucose. When the cells 
produce  more  insulin  molecules,  the  current  in  the  sensor  increases  and  vice  versa,  allowing  monitoring  insulin 
concentrations in real time. This data could then be fed to an embedded microchip, which could send the data wirelessly to a  
wearable computer.4, 5
2.1.2 By Implantable Sensor ("smart Tattoo"):  Use of polyethylene glycol beads coated with fluorescent molecules to 
monitor diabetes blood sugar levels is very effective in this method the beads are injected under the skin and stay in the  
interstitial fluid. When glucose in the interstitial fluid drops to dangerous levels, glucose displaces the fluorescent molecules 
and creates a glow. This glow is seen on a tattoo placed on the arm.
Sensor  microchips  are  also  being  developed  to  continuously  monitor  key  body  parameters  including  pulse, 
temperature and blood glucose. A chip would be implanted under the skin and transmit a signal that could be monitored 
continuously.
Figure 1. The "pin-prick" glucose test could be replaced with more accurate and convenient methods using 
nanotechnology.
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2.2 Use of nanotechnology in the treatment of diabetes:
2.2.1 Polymeric  Nanoparticles: Polymeric nanoparticles have been used as carriers of insulin. These are biodegradable 
polymers, with the polymer–insulin matrix encloseed by the nanoporous membrane containing grafted glucose oxidase. A 
rise in blood glucose level triggers a change in the surrounding nanoporous membrane, resulting in biodegradation and 
subsequently release insulin. The glucose/glucose oxidase reaction causes a reducing the pH in the delivery system’s. This 
can cause an increase in the swelling of the polymer system, leading to an increased release of insulin. The polymer systems  
examined for such applications include copolymers such as N,N-dimethylaminoethyl methacrylate and polyacrylamide. 
This  “molecular  gate” system is  composed of  an insulin  reservoir  and a delivery rate–controlling membrane made of 
poly[methacrylic acid-g-poly(ethylene glycol)] copolymer. The polymer swells in size at normal body pH (pH = 7.4) and 
closes the gates. It shrinks at low pH (pH = 4) when the blood glucose level increases, thus opening the gates and releasing 
the insulin from the nanoparticles. These systems release insulin by swelling caused due to changes in blood pH. The  
control of the insulin delivery depends on the size of the gates, the concentration of insulin, and the rate of gates’ opening or 
closing (response rate). These self-contained polymeric delivery systems are still under research, whereas the delivery of 
oral insulinwith polymeric nanoparticles has progressed to a greater extent in the recent years. 2, 7
Fig 2: Schematic of polymeric nanoparticles with pH-sensitive molecular gates for controlled insulin release 
triggered by the presence of glucose in blood
2.2.2 Oral Insulin By Using Polysaccharides And Polymeric Nanoparticles: Polysaccharides are natural biodegradable 
hydrophilic polymers,  which exhibit enzymatic degradation behavior and good biocompatibility16.  The development of 
improved oral insulin administration is very essential for the treatment of diabetes mellitus to overcome the problem of 
daily subcutaneous  injections.  Insulin,  when administered orally,  undergoes degradation in  the  stomach due to  gastric  
enzymes. Therefore, insulin should be enveloped in a matrix like system to protect it from gastric enzymes. This can be  
achieved by encapsulating the insulin molecules in polymeric nanoparticles. In one such study, calcium phosphate–poly 
(ethylene glycol)–insulin combination was combined with casein (a milk protein). The casein coating protects the insulin 
from the gastric enzymes. Due to casein’s mucoadhesive property,  the formulation remained concentrated in the small  
intestine for a longer period, resulting in slower absorption and longer availability in the bloodstream.2,7
2.2.3Insulin Delivery Through Inhalable Nanoparticles: Inhalable, polymeric nanoparticle-based drug delivery systems 
have been tried earlier for the treatment of tuberculosis. Such approaches can be directed toward insulin delivery through  
inhalable nanoparticles. Insulin molecules can be encapsulated within the nanoparticles and can be administered into the  
lungs by inhaling the dry powder formulation of insulin. The nanoparticles should be small enough to avoid clogging up the  
lungs but large enough to avoid 414 being exhaled. Such a method of administration allows the direct delivery of insulin  
molecules to the bloodstream without undergoing degradation. A few studies have been done to test the potential use of  
ceramic nanoparticles (calcium phosphate) as drug delivery agents. Porous hydroxyapatite nanoparticles have also been 
tested for the intestinal delivery of insulin. Preclinical  studies in guinea pig lungs with insulin-loaded poly (lactide-co-
glycolide) nanospheres demonstrated a significant reduction in blood glucose level with a prolonged effect over 48 hours 
when compared with insulin solution. Insulin-loaded poly (butyl cyanoacrylate) nanoparticles when delivered to the lungs 
of  rats  were  shown  to  extend  the  duration  of  hypoglycemic  effect  over  20  hours  when  compared  with  pulmonary 
administration of insulin solution. The major factors limiting the bioavailability of nasally administered insulin include poor 
permeability across the mucosal membrane and rapid mucociliary clearance mechanism that removes the non mucoadhesive 
formulations  from  the  absorption  site.  To  overcome  these  limitations,  mucoadhesive  nanoparticles  made  of  
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chitosan/tripolyphosphate and starches have been evaluated. These nanoparticles showed good insulin-loading capacity, 
providing the release of 75% to 80% insulin within 15 minutes after administration. 2, 8
2.2.4 Applications Of Nanotechnology In Diabetes:Diabetes is considered to be one of the major afflictions of modern 
western  society.  To  date,  diabetic  patients  control  their  blood-sugar  levels  via  insulin  introduced  directly  into  the  
bloodstream using injections. This unpleasant method is required since stomach acid destroys protein-based substances such 
as Insulin, making oral insulin consumption useless. The new system is based on inhaling the insulin (instead of injecting it) 
and on a controlled release of insulin into the bloodstream (instead of manually controlling the amount of insulin injected).  
The  treatment  of  diabetes  includes  the  proper  delivery  of  insulin  in  the  blood  stream  which  can  be  achieved  by  
nanotechnology in the following ways:
2.2.5 Development Of Oral Insulin:Production of pharmaceutically active proteins, such as insulin, in large quantities has 
become feasible. The oral route is considered to be the most convenient and comfortable means for administration of insulin  
for less invasive and painless diabetes management, leading to a higher patient compliance. Nevertheless, the intestinal  
epithelium is a major barrier to the absorption of hydrophilic drugs, as they cannot diffuse across epithelial cells through  
lipid-bilayer cell membranes to the bloodstream. Therefore, attention has been given to improving the paracellular transport  
of hydrophilic drugs. A variety of intestinal permeation enhancers including chitosan(CS) have been used for the assistance 
of the absorption of hydrophilic macromolecules. Therefore, a carrier system is needed to protect protein drugs from the 
harsh environment in the stomach and small intestine, if given orally. Additionally, CS nanoparticles (NPs) enhanced the 
intestinal absorption of protein molecules to a greater extent than aqueous solutions of CS in vivo.
The insulin loaded NPs coated with mucoadhesive CS may prolong their residence in the small intestine, infiltrate  
into  the  mucus  layer  and  subsequently  mediate  transiently  opening  the  tight  junctions  between  epithelial  cells  while 
becoming unstable and broken apart due to their pH sensitivity and/or degradability. The insulin released from the broken-
apart NPs could then permeate through the paracellular pathway to the bloodstream, its ultimate destination.
2.2.6 Microsphere For Oral Insulin Production:  The most promising strategy to achieve oral insulin is the use of a 
microsphere system which is inherently a combination strategy. Microspheres act both as protease inhibitors by protecting 
the encapsulated insulin from enzymatic degradation within its matrix and as permeation enhancers by effectively crossing 
the epithelial layer after oral administration.
2.3 Artificial  Pancreas:  Development of artificial  pancreas could be the permanent solution for diabetic patients.  The 
original idea was first described in 1974. The concept of its work is simple: a sensor electrode repeatedly measures the level  
of blood glucose; this information feeds into a small computer that energizes an infusion pump, and the needed units of  
insulin enter the bloodstream from a small reservoir.
Another way to restore body glucose is the use of a tiny silicon box that contains pancreatic beta cells taken from  
animals. The box is surrounded by a material with a very specific nanopore size (about 20 nanometers in diameter). These 
pores are big enough to allow for glucose and insulin to pass through them, but small enough to impede the passage of much 
larger immune system molecules. These boxes can be implanted under the skin of diabetes patients. This could temporarily 
restore the body’s delicate glucose control feedback loop without the need of powerful immunosuppressant that can leave  
the patient at a serious risk of infection.
Scientists are also trying to create a nano-robot which would have insulin departed in inner chambers, and glucose 
level sensors on the surface. When blood glucose levels increase, the sensors on the surface would record it and insulin  
would be released. Yet, this kind of nano-artificial pancreas is still only a theory.1, 2, 8
3. The Nanopump
The nanopump is a powerful device and has many possible applications in the medical field. The first application  
of the pump, introduced by Debiotech, is Insulin delivery. The pump injects Insulin to the patient's body in a constant rate,  
balancing the amount of sugars in his or her blood. The pump can also administer small drug doses over a long period of  
time.9
4. Summary And Conclusion
Diabetes mellitus, often simply referred to as diabetes—is a group of metabolic diseases in which a person has high  
blood sugar, either because the body does not produce enough insulin, or because cells do not respond to the insulin that is  
produced. This high blood sugar produces the classical symptoms of polyuria (frequent urination), polydipsia (increased 
thirst) and polyphagia (increased hunger). It is the most common endocrine disorder and by the year 2012, it is estimated  
that more than 200 million people worldwide will have DM and 300 million will subsequently have the severe diabetic 
complication such as retinopathy, neuropathy, nephropathy, cardiovascular complication and ulceration. 
Nanotechnology can be defined as the monitoring, repairing, construction and control of human biological systems 
at the cellular level by using materials and structures engineered at the molecular level. It is useful in detection of insulin  
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and blood sugar by the help of microphysiometer and implantable sensors. By using nanotechnology the nanoparticles were 
formed  and  these  nanoparticles  are  also  useful  in  treatment  of  diabetes.  In  which  a)  a  polymeric  nanoparticle  these  
polymeric nanoparticles have been used as carriers of insulin for giving targeted site of action b) oral insulin administration  
by using polysaccharides and polymeric nanoparticles the development of improved oral  insulin administration is very 
essential for the treatment of diabetes mellitus to overcome the problem of daily subcutaneous injections c) insulin delivery 
through  inhalable  nanoparticles  in  this  insulin  molecules  can  be  encapsulated  within  the  nanoparticles  and  can  be  
administered into the lungs by inhaling the dry powder formulation of insulin, this will be an effective in treatment of  
diabetes. And its applications in developments of oral insulin, microsphere for oral insulin production, development of 
artificial pancreas, nanopumps the pump injects Insulin to the patient's body in a constant rate, balancing the amount of 
sugars in his or her blood. The pump can also administer small drug doses over a long period of time. These are all about the 
disease diabetes in which the nanotechnology helps in the treatment of diabetes and its recent advances used for diabetes  
treatment.
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